Olanzapine pamoate for the treatment of schizophrenia.

TY - JOUR

T1 - Olanzapine pamoate for the treatment of schizophrenia.

AU - Naber, Dieter

PY - 2011

Y1 - 2011

N2 - Introduction: Nonadherence is still a major problem in the long-term treatment of schizophrenia. Long-acting injectable or depot atypical antipsychotics are associated with better maintenance. Olanzapine pamoate, available since 2010, is the second depot atypical antipsychotic. Areas covered: This review covers data on the efficacy and tolerability/safety of olanzapine pamoate, the long-acting formulation of the atypical antipsychotic olanzapine. Administered as a pamoate salt, it has an elimination half-life of 30 days, allowing a 2- or 4-week injection interval. Antipsychotic efficacy was documented in an 8-week trial in 404 acutely ill schizophrenia patients with maintenance therapy in a 24-week trial in 1065 chronic patients. The side-effect profile is comparable to that of oral olanzapine. The most relevant adverse event is the post-injection delirium/sedation syndrome, occurring at a rate of 0.07% of injections or 1.4% of patients. It requires administration by qualified personnel in settings where a post-injection observation period for 3 h by medical personnel is available. Expert opinion: Olanzapine pamoate is an efficacious formulation, particularly for patients with a history of good response to oral olanzapine and doubtful adherence. Psychiatrists should reconsider their negative attitudes toward long-acting or depot antipsychotics and should offer this administration to the majority of patients, not only to a negatively selected population.

AB - Introduction: Nonadherence is still a major problem in the long-term treatment of schizophrenia. Long-acting injectable or depot atypical antipsychotics are associated with better maintenance. Olanzapine pamoate, available since 2010, is the second depot atypical antipsychotic. Areas covered: This review covers data on the efficacy and tolerability/safety of olanzapine pamoate, the long-acting formulation of the atypical antipsychotic olanzapine. Administered as a pamoate salt, it has an elimination half-life of 30 days, allowing a 2- or 4-week injection interval. Antipsychotic efficacy was documented in an 8-week trial in 404 acutely ill schizophrenia patients with maintenance therapy in a 24-week trial in 1065 chronic patients. The side-effect profile is comparable to that of oral olanzapine. The most relevant adverse event is the post-injection delirium/sedation syndrome, occurring at a rate of 0.07% of injections or 1.4% of patients. It requires administration by qualified personnel in settings where a post-injection observation period for 3 h by medical personnel is available. Expert opinion: Olanzapine pamoate is an efficacious formulation, particularly for patients with a history of good response to oral olanzapine and doubtful adherence. Psychiatrists should reconsider their negative attitudes toward long-acting or depot antipsychotics and should offer this administration to the majority of patients, not only to a negatively selected population.

KW - Humans

KW - Medication Adherence

KW - Delayed-Action Preparations

KW - Antipsychotic Agents/administration & dosage/adverse effects/therapeutic use

KW - Benzodiazepines/administration & dosage/adverse effects/therapeutic use

KW - Injections, Intramuscular

KW - Receptors, Dopamine D2/metabolism

KW - Schizophrenia/drug therapy/physiopathology

KW - Humans

KW - Medication Adherence

KW - Delayed-Action Preparations

KW - Antipsychotic Agents/administration & dosage/adverse effects/therapeutic use

KW - Benzodiazepines/administration & dosage/adverse effects/therapeutic use

KW - Injections, Intramuscular

KW - Receptors, Dopamine D2/metabolism

KW - Schizophrenia/drug therapy/physiopathology

M3 - SCORING: Journal article

VL - 12

SP - 627

EP - 633

JO - EXPERT OPIN PHARMACO

JF - EXPERT OPIN PHARMACO

SN - 1465-6566

IS - 4

M1 - 4

ER -